Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

July 13th 2023

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Efficacy of Subsequent Therapies in Advanced Ovarian Cancer

July 13th 2023

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Immuno-Oncology Approaches Continue to Advance Across Gynecologic Cancers

July 11th 2023

Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.

Dr Williams on Frontline Niraparib Maintenance Therapy in Ovarian Cancer

July 7th 2023

Heather R. Williams, MD, discusses findings from the phase 3 PRIMA trial in patients with ovarian cancer.

Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer

July 6th 2023

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

Unmet Needs in the Maintenance Setting in Ovarian Cancer

July 6th 2023

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

Ovarian Cancer: Deciding Between Treatment Options

June 29th 2023

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

Frontline Maintenance Therapy in Ovarian Cancer

June 29th 2023

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

Rapid Accelerating Changes in Cancer Management Through the Lens of Ovarian Cancer

June 13th 2023

Maurie Markman, MD, discusses changes in cancer management as seen in ovarian cancer.

Dr Disis on the Investigation of the CAR T-Cell Therapy PRGN-3005 in Ovarian Cancer

June 12th 2023

Mary “Nora” Disis, MD, discusses the results of a phase 1/1b study of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.

Majority of US Cancer Centers Report Shortages of Cisplatin/Carboplatin Chemotherapy

June 7th 2023

A survey conducted by the National Comprehensive Cancer Network Best Practices Committee found that 93% of United States cancer centers polled in the report are experiencing a shortage of carboplatin, and 70% currently have a shortage of cisplatin.

Avutometinib Plus Defactinib Demonstrates Promising Activity in Recurrent LGSOC

June 6th 2023

Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the RAMP 201 trial.

Post-hoc Analysis Shows Maintenance Niraparib Provides Additional Antitumor Activity in Advanced Ovarian Cancer

June 6th 2023

The use of maintenance niraparib enhanced antitumor activity and led to a clinically meaningful increase in progression-free survival vs placebo for patients with newly diagnosed advanced ovarian cancer who displayed measurable residual disease after first-line platinum-based chemotherapy, according to findings from a post hoc subgroup analysis of the phase 3 PRIME study.

Mirvetuximab Soravtansine Positioned as New Standard in Frα+ Platinum-Resistant Ovarian Cancer

June 4th 2023

Mirvetuximab soravtansine-gynx demonstrated a 35% reduction in the risk of disease progression or death compared with investigator’s choice of chemotherapy in patients with folate receptor alpha-high, platinum-resistant ovarian cancer.

Addition of Up-front Durvalumab, Maintenance Olaparib to Standard Therapy Improves PFS in Advanced Ovarian Cancer

June 3rd 2023

The addition of durvalumab to standard upfront therapy with chemotherapy and bevacizumab followed by maintenance bevacizumab, durvalumab, and olaparib led to a statistically significant improvement in progression-free survival compared with chemotherapy and bevacizumab alone in patients with newly diagnosed, advanced ovarian cancer without a BRCA1/2 mutation.

PARP Inhibitors Represent Effective Upfront Ovarian Cancer Treatment Options

May 31st 2023

Whitfield B. Growdon, MD, shares the potential implications of first-line PARP maintenance in newly diagnosed ovarian cancer, the importance of treating patients with effective therapies as early as possible, and where combination regimens could fit into the treatment paradigm going forward.

Future Outlook of Advanced Ovarian Cancer Treatment

May 30th 2023

Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.

Advanced Ovarian Cancer: Current Treatment Landscape in Second- and Later-Line Settings

May 30th 2023

Expert oncologists review the current PARP inhibitor treatment indications for patients with advanced ovarian cancer and discuss how to best manage patients who have been impacted by the recent updates to the PARP inhibitors.

Advanced Ovarian Cancer: Updated Indications for PARP Inhibitors in Second- and Later-Line Settings

May 30th 2023

Drs Coleman and Monk discuss what led to the recent withdrawal of several indications for PARP inhibitors in the treatment of advanced ovarian cancer.

Role of PARP Inhibitors in Advanced Ovarian Cancer

May 30th 2023

Expert oncologists give an overview of PARP inhibitors available for the treatment of patients with advanced ovarian cancer and review adverse events seen with each agent.